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ABSTRACT
Citrobacter rodentium infection is a murine model for pathogenic intestinal Escherichia coli infec-
tion. C. rodentium infection causes an initial decrease in mucus layer thickness, followed by an
increase during clearance. We aimed to identify the cause of these changes and to utilize this
naturally occurring mucus stimulus to decrease pathogen impact and inflammation. We identified
that mucin production and speed of transport from Golgi to secretory vesicles at the apical
surface increased concomitantly with increased mucus thickness. Of the cytokines differentially
expressed during increased mucus thickness, IFN-γ and TNF-α decreased the mucin production
and transport speed, whereas IL-4, IL-13, C. rodentium and E. coli enhanced these aspects. IFN-γ
and TNF-α treatment in combination with C. rodentium and pathogenic E. coli infection negatively
affected mucus parameters in vitro, which was relieved by IL-4 treatment. The effect of IL-4 was
more pronounced than that of IL-13, and in wild type mice, only IL-4 was present. Increased
expression of Il-4, Il-4-receptor α, Stat6 and Spdef during clearance indicate that this pathway
contributes to the increase in mucin production. In vivo IL-4 administration initiated 10 days after
infection increased mucus thickness and quality and decreased colitis and pathogen contact with
the epithelium. Thus, during clearance of infection, the concomitant increase in IL-4 protects and
maintains goblet cell function against the increasing levels of TNF-α and IFN-γ. Furthermore, IL-4
affects intestinal mucus production, pathogen contact with the epithelium and colitis. IL-4 treat-
ment may thus have therapeutic benefits for mucosal healing.
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Introduction
Enterotoxigenic Escherichia coli (ETEC) causes diarrhea
through secretion of enterotoxins, whereas enteropatho-
genic E. coli (EPEC) and enterohaemorrhagic E. coli
(EHEC) induce attaching and effacing (A/E) lesions on
intestinal epithelial cells.Citrobacter rodentium is a mouse
pathogen that uses the same mechanism as EPEC and
EHEC to colonize epithelial cells. During the mid-point of
infection, the host response to C. rodentium is primarily
Th1/Th17 driven, whereas cytokines of “Th2/anti-
inflammatory” type appear during clearance: interferon
gamma (Ifn-γ) and interleukin (IL) Il-12 become up-
regulated throughout infection whereas Il-4, tumor necro-
sis factor alpha (Tnf-α) and Il-6 mRNA become upregu-
lated during clearance only [1].
Colonic mucus consists of two layers: an inner, firm,
nominally sterile layer and an outer, loose layer, which
is a niche for commensal bacteria [2]. Bacterial pene-
tration of the inner mucus layer and access to the
epithelium are important determinants of colitis, both
in murine colitis models and in ulcerative colitis [3].
The highly glycosylated MUC2 mucin is the main
component of colonic mucus and is secreted constitu-
tively by goblet cells [4]. Components released from
microbes (e.g. lipopolysaccharide) as well as factors
produced by innate and adaptive immune responses
can cause mucin discharge [4,5]. IL-13 induces goblet
cell proliferation during Trichinella spiralis infection
[6], and treatment with IL-13 secreting cells results in
increased Alcian blue staining of acidic mucins in tissue
of mice with asthmatic airway inflammation [7,8]. In
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contrast, simultaneous addition of IFN-γ and TNF-α to
cultured cells render them devoid of mucus granules
[9]. Thus, a Th1 type response (common to Gram
negative bacteria such as E. coli and C. rodentium) is
associated with parameters that could indicate a mucus
decrease, whereas IL-13 has been linked to a mucin
increase. However, neither mucin mRNA levels, nor
the amount of mucin in the tissue, correspond unam-
biguously to mucus formation [10], since this depends
on factors such as post translational regulation, mucin
production, transport and secretion.
C. rodentium infection in mice lacking Muc2 results
in high mortality, whereas wild type (WT) mice clear
the infection spontaneously [11], and clearance is
delayed in mice with defective mucus exocytosis [12].
C. rodentium bind to Muc2, and high numbers of
bacteria are found among secreted Muc2 in infected
animals, indicating that mucins may limit bacterial
access to the epithelial surface or aid in transport of
the pathogen from the epithelium [13]. The current
knowledge indicates that the cytokine environment,
IgG and mucins are important for eliminating A/E
pathogens [14,15]. Cytokines affect mucin production
in allergic reactions, worm infection and chronic infec-
tion [16–22], however, the mucus related events that
occur during natural clearance of bacteria have yet to
be elucidated. Here, we identified that the increased
mucus thickness that occur during clearance of
in vivo C. rodentium infection is accompanied by
increased mucin glycoprotein production and the cyto-
kine environment determined the mucus thickness dur-
ing infection. The effects of the cytokines differentially
expressed concurrently with increased mucus thickness
on mucus related parameters were investigated in vitro
in the presence and absence of C. rodentium, ETEC and
EPEC infection. Together, these results indicated that
the IL-4/signal transducer and activator of transcription
6 (Stat6) pathway was important for intestinal mucus
production during infection, and finally we demon-
strated a role of the IL-4/Stat6 pathway in mucosal
healing, recovery of the mucus layer and removal of
the pathogen from contact with the epithelium by sti-
mulating versus inhibiting the pathway during in vivo
infection.
Methods
Ethics statement
All experimental procedures were approved by the
Göteborgs Djurförsöksetiska Nämnd (Ethic No. 261/
09 and 57–2016) based on the regulation from
Djurskyddsförordningen DFS 2004:4. The ETEC and
EPEC strains have been deposited at the ETEC culture
collection of University of Gothenburg and in the
group of Å. Sjöling. Permission to use the strain collec-
tion was granted by the Regional Ethical Board of
Gothenburg, Sweden (Ethics Committee Reference
088–10). All samples were anonymized.
Animals
For the experiments shown in Figures 1, 2 and 6, 8–12-
week old, specific-pathogen-free, male C57BL/6 (Charles
Rivers, Germany) and IFN-γ-deficient (IFN-γ−/-) [23]
mice on a C57BL/6 background, were bred in ventilated
cages under pathogen-free conditions at the Laboratory
for Experimental Biomedicine at Sahlgrenska Academy,
Gothenburg University (Gothenburg, Sweden). For the
remainder of the experiments, 8-week old male C57BL/6
mice were purchased (Charles Rivers, Germany) and
housed under pathogen-free conditions at the
Department of Rheumatology and Inflammation
Research, University of Gothenburg (control/IL-4/Stat6
cohort 1) or in individually ventilated cages at the
Laboratory for Experimental Biomedicine, Gothenburg
University (control/IL-4/Stat6 cohort 2). The animals
had a 12 h light/dark cycle, free access to water and food
throughout the experiment and were monitored daily for
the duration of the study.
Infection and treatments in vivo
C. rodentium strain ICC169 grown on MacConkey agar
(CM0007, Oxoid) for 20 h at 37°C were suspended in
Luria-Bertani broth to an OD600 of 0.8. Male C57BL/6
mice were infected with 5 × 109 CFU by oral gavage.
Incorporation of GalNAz: A total volume of 0.5 ml
per mouse of GalNAz (C33365, Invitrogen) was pre-
pared by dissolving 2.6 mg of GalNAz in 50 µl dimethyl
sulfoxide (DMSO, A3672, AppliChem) and diluted in
phosphate buffered saline (PBS) (0.15 mol/L NaCl,
5 mmol/L Na2HPO4 buffer, pH 7.4). The GalNAz
injections were given intraperitoneally and mice were
sacrificed 3 h after the injection.
Stat6 inhibitor and IL-4 treatment: The control/IL-4/
Stat6 cohort 1 contained 4–5 mice in each treatment
group, harvested at 14 days post infection (dpi) whereas
the control/IL-4/Stat6 cohort 2 contained 5–6 mice in each
treatment group for each harvest time point (13 and 22
dpi).Mice received either recombinant IL-4 (0.2 µg/mouse,
I1020, Sigma-Aldrich, dose determined after a pilot experi-
ment suggested that both 2 ng and 2 µg/100gmouse weight
had an effect and the dose range for the pilot was deter-
mined previously [24,25]), Stat6 inhibitor (AS1517499,
1992, Axon, 10 mg/kg body weight, dose in accordance
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with a previous study [26]), or a second inhibitor acting
downstream of Stat6 (RCM-1, GLXC- 10,156, Glixx
Laboratories, 1.7 mg/kg body weight, dose in accordance
with a previous study [27]) dissolved in sterile PBS
containing 20% DMSO (A3672, AppliChem) and 1%
bovine serum albumin (BSA, Sigma-Aldrich) for protein
stabilization. Control mice received sterile PBS containing
20%DMSO and 1% BSA (vehicle). Treatments were admi-
nistered by intraperitoneal injections in a volume of 0.1 ml
for three consecutive days (for cohort 1: from day 11 to day
13, cohort 2: day 10 to day 12 pi) andmice harvested at day
22 received two additional injections on day 15 and 17 pi.
In the results section, we show data from the AS1517499
Stat6 inhibitor. To verify the results with the AS1517499
Stat6 inhibitor, we treated four additional mice harvested
at day 13 pi with a second inhibitor (RCM-1), and the
parameters bacterial localization, density and colitis scores
matched those from the AS1517499 treatment.
Harvest: mice were anesthetized with isoflurane and
sacrificed by CO2 and cervical dislocation. Starting at
the anal verge, colon samples were collected. The most
distal 1–2 cm colonic specimens were collected in ice
cold transport KREBs buffer for mucus thickness mea-
surements. The second distal 0.5 cm of colon was
harvested into 0.5 ml fresh Carnoy’s methanol fixative
(60% dry methanol, 30% chloroform, 10% glacial acetic
acid) and the next 0.5 cm into 200 µl RNAlater
(AM7020 Thermo Fisher Scientific). For cohort 2, the
next 1.5 cm was harvested for flow cytometry.
qPCR
Distal colon samples (0.5 cm) were collected in
RNAlater and kept at 4ºC overnight, then at −80ºC.
For the analysis of mucin genes, total RNA was
extracted using the RNeasy mini kit (74,104, QIAGEN
following the manufacturer’s protocol. The QuantiTect
Reverse Transcription kit (20,531, QIAGEN) was used
for cDNA preparation from extracted RNA of each
sample, according to the manufacturer’s protocol.
SYBRGreen based real time qPCR was carried out
using primers for Muc1, Muc2, Muc4, Muc6, Muc13,
Clca3, using previously published primers [10]. Data
were normalized with the Hprt-1 housekeeping gene
from QIAGEN. Fold changes were calculated using
the ΔΔCT method with the mean of CT from three
non-infected mice as control. Fold changes ≥4 were
accepted as up-regulation and ≤0.25 as down-
regulation. Murine gastric tissue was used as
a positive control for Muc1. For the qPCR cytokine
array, mRNA from two sets of two mice in each
group were pooled for the time points of day 0
and day 10 (i.e. data are representative of four mice in
each group), whereas the time points day 14 and 19
contained mRNA pooled from three mice in each
group. The QuantiTect Reverse Transcription kitwas
used for cDNA preparation according to the manufac-
turer’s protocol. qPCR on pooled samples was carried
out in duplicates using RT2 Profiler™ PCR Array
(PAMM-034Z, QIAGEN) plates containing 84 mouse
inflammatory cytokines, chemokines and receptor
genes. The array plates were run on an ABI 7500 real-
time PCR system (Applied Biosystems). Intra-plate
controls were included and data were normalized by
the RT2 Profiler™ PCR Array data analysis software
(QIAGEN) using the most suitable housekeeping gene
chosen from five housekeeping genes (Gusb, Hprt1,
Hsp90ab1, Gapdh, Actb) with a threshold of variance
of only 0.2 cycles. The means of two technical replicates
were used to calculate fold changes against control mice
using the same software. Fold changes ≥2.5 were
accepted as up-regulation and ≤0.4 as down regulation,
in compliance with instructions from the array manu-
facturer. Protein interactions were analyzed by the
database and web-tool STRING v10 (Search Tool for
the Retrieval of Interacting Genes/Proteins) [28]. The
interactions include both physical and functional asso-
ciations derived from numerous sources, including
experimental repositories and public text collections.
To verify the cytokine array results and pathways
involved in mucin regulation during infection with
individual qPCRs, total RNA was extracted from
an additional three non-infected WT control mice
and three mice from 19 dpi using TRizol (15596018,
Thermo Fisher Scientific). RNA purity was assessed
through UV spectroscopy (NanoDrop; Thermo Fisher
Scientific). Total RNA (for cytokines 5 μg, and path-
ways 7.5 μg) was treated with DNase at 37°C for 30
min, addition of 5mM ethylenediaminetetraacetic acid
(EDTA) and heat inactivation of DNase at 75°C for
10 min followed by cDNA synthesis. A final concentra-
tion of 5 mM MgCl2 was added to RNA samples, which
were later used for cDNA synthesis by adding oligo-
(dT) primers and Superscript III (18080093, Thermo
Fisher Scientific) at 50°C for 2 h. The cDNA was used
in a qPCR using EvaGreen (172520, Bio-Rad
Laboratories) with Il-4, Tnf-α, Ifn-γ Stat6, Spdef,
Myd88 (QIAGEN) and Nfκb1 (Fwd:
GAACGATAACCTTTGCAGGC, Rev:
TTTCGATTCCGCTATGTGTG); designed using
Primer depot https://mouseprimerdepot.nci.nih.gov/
cgi-bin/testdb2.pl) primers. The expression of Hprt1
(QT00166768, QIAGEN) was used for normalizing the
qPCR data. Samples were amplified in triplicate with
a negative control without reverse transcriptase to
confirm the lack of contaminating genomic DNA.
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Data acquisition and analysis were performed using
CFX manager 3.1 software (Bio-Rad Laboratories).
Mucus measurements
Mucus thickness comparisons between WT and IFN-
γ−/- mice:
Following incubation on ice for 30 min, the long-
itudinal muscle was removed and the tissue was
mounted in the perfusion chamber. The apical and
basolateral solution was KREB’s buffer (115.8 mM
NaCl, 1.3 mM CaCl2, 3.6 mM KCl, 1.4 mM KH2PO4,
23.1 mM NaHCO3, 1.2 mM MgSO4, Merck) containing
5.7 mM Na-Pyruvate, 5.1 mM Na-L-Glutamate and
10 mM D-Glucose for the basolateral compartment,
whereas the apical compartment was immersed in
KREB’s buffer containing 5.7 mM Na-Pyruvate,
5.13 mM Na-L-Glutamate and 10 mM D-Mannitol.
The solutions were gassed with 95% O2 and 5% CO2
prior to the experiment and pH was set to 7.4. The
perfusion chamber was heated to 37°C and kept at
a constant temperature throughout the whole experi-
ment. Tissue viability was measured using transepithe-
lial potential difference (PD) recordings. To visualize
the colonic mucus layer a suspension of activated char-
coal particles was added to the apical surface and
allowed to sediment down to the top of the mucus
layer. The thickness of the mucus layer was assessed
by measuring the distance between the top of the
mucus layer, and the epithelial surface using
a micropipette (tip diameter, 5–10 µm) connected to
a micromanipulator.
Ex vivo imaging of mucus in WT infected mice with
and without IL-4 treatment
Live imaging of colonic explants was performed as
described previously [29,30], with slight modifications.
Briefly, 1.5 cm of distal colon was removed by dissection
and flushed with ice cold KREB’s buffer. The tissue was
cut open along the mesentery border, with the muscle
layer kept intact, and mounted in a horizontal perfusion
chamber. Staining of the tissue was performed by 10 min
apical incubation of 200 µl Calcein violet (C34858,
Invitrogen; 6 µg/ml) in KREB’s-Mannitol. Thereafter,
10 µl of FluoSphere Carboxylate-Modified Microspheres
1 µm (F8816, Invitrogen; 1:10) in KREB’s-Mannitol was
added and left to sediment for 5 min. Excess beads were
removed by gentle washing prior to confocal imaging.
Four Z-stacks per animal was acquired with an LSM700
Examiner Z.1 upright confocal microscope with Plan-
Apochromat x20/1.0DIC water objective and Zen ima-
ging software (Zeiss). Mucus penetrability was assessed
based on the number of beads in contact with the epithe-
lium. Beads were counted manually in the combined
tissue area of all four Z-stacks (0.4 mm2 per animal)
using Volocity 5.5.1 software (Perkin-Elmer). Mucus
thickness was calculated as the average distance between
beads and epithelium. The Z-positions were extracted by
mapping tissue and bead Isosurfaces in Imaris Software
(Bitplane). A flat tissue area of 150 × 150 µm in XY-plane
from three Z-stacks per animal was used for the analysis.
In vitro mucosal surfaces
HT29 MTX-E12 cells (derived from MTX selected col-
orectal adenocarcinoma cells HT29, ATCC) were cul-
tured in RPMI medium (BE12-702F/U1, Lonza)
containing 10% (V/V) fetal bovine serum (FBS), 1%
(V/V) penicillin G sodium and streptomycin (DE17-
603E, Lonza). The cells were plated on snapwell tissue
culture inserts (0.4 μm pores, 1.12 cm in diameter,
3407, Corning) at a density of 7.5 × 104 cells/well
under standard conditions (media added: 4 ml to the
basolateral and 200 µl to the apical compartment) until
complete confluency. The cells were then changed to
semi-wet interface with mechanical and chemical sti-
mulation as described previously [31,32]. Briefly, the
basolateral and apical media were changed to 2 ml and
50 µl respectively, and 10 µM of the Notch γ-secretase
inhibitor (DAPT, D5942, Sigma-Aldrich) was added to
the basolateral media during the first 6 days of semi-
wet interface, and plates were placed on a rocking
board at 37ºC, 5% CO2, atmospheric O2 for 34 days.
In vitro cytokine treatment: For cytokine treatment
and infection studies cell culture media were changed
into antibiotic-free RPMI (BE12-702F/U1, Lonza) with
10% FBS at day 30 post confluency, and designated
concentrations of different cytokines were added to
the basolateral media. The concentration of cytokines
used in the cell treatment is presented in Table 1. The
concentration of each cytokines was chosen based on
previous work that was either related to immune
responses, mucin production or the non-destructive
effect on the in vitro mucosal surface [33–38].
In vitro incorporation of GalNAz: 5.2 mg of GalNAz
was dissolved in 1 ml DMSO and diluted in 250 ml of
culture media (RPMI with 10% FBS) without antibio-
tics. Then 1 ml of the basolateral media of each well
was replaced with media containing GalNAz. The
membrane was collected in Methanol Carnoy’s fixative
2 h after addition of GalNAz.
In vitro infection: C. rodentium strain ICC169, ETEC
strain number E2265 (isolated from an adult patient with
diarrhea in Dhaka, Bangladesh [39] and EPEC strain 38068
(positive for eae and bfp, Culture Collection, University of
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Gothenburg, Sweden), were grown onMacConkey agar for
20 h at 37°C, then harvested from the plate in sterile PBS.
For infection, 10 µl of C. rodentium and E. coli suspensions
with a respectiveODof 2.0 and 0.1 at 410 nm (CFU: 1 x 107
and 5 × 105 CFU, corresponding to a multiplicity of infec-
tion of 10:1 and 0.5:1) in sterile PBS was added to the apical
side of theHT29-MTX-E12 based in vitromucosal surfaces
24 h prior to collecting them in Carnoy’s methanol fixative.
Histological stains
PAS/Alcian blue stain: deparaffinized sections were
immersed in 100% ethanol for 10 min, rinsed in water
for 10 min, immersed in 3% acetic acid for 2 min and
stained in 1% Alcian Blue (AB) 8GX (A5268, Sigma-
Aldrich) in 3% acetic acid (pH 2.5) for 2.5 h. Non-
specific stain was removed with 3% acetic acid and
sections were rinsed in water for 10 min. The slides
were then oxidized in 1% periodic acid in water at
room temperature for 10 min, washed in water for
5 min, immersed in Schiff’s reagent (3,952,016, Sigma-
Aldrich) for 10 min, rinsed in water for 5 min and then
incubated three times in 0.5% sodium meta-bisulfite
before a final wash in water. ImageJ was used to quan-
tify the percentage of tissue that stained positive for
AB/PAS in the total distal colon area. ImageJ is a public
domain image processing program (Wayne Rasband at
the Research Services Branch (RSB) of the National
Institute of Mental Health (NIMH), National
Institutes of Health, Maryland, USA). Morphology of
the cell lines was scored in a blinded fashion at 20x
magnification and is expressed as the sum of the indi-
vidual scores for number of crypt like structures (0–3),
integrity of the epithelial layer (0–3) and AB/PAS posi-
tive material in the surface cells (0–3). The total section
of undamaged membrane was scored; for treatments
that severely affected the membranes (i.e. ETEC infec-
tion in combination with TNF-α and IFN-γ), large
parts of the membrane and sometimes the entire mem-
brane was lost during processing, leading to the pre-
sented scores most likely underestimating the level of
damage, as the most damaged parts were the parts that
became more fragile and lost. Furthermore, this
resulted in a low n for those treatments.
For the total colitis score of infected mice, tissue
sections were stained with haematoxylin/eosin (H/E)
and slides were coded to blind the analysis. The full
section was systematically scored for: crypt architecture
(0–4), tissue damage (0–4), crypt length (0–4), neutro-
phil count in lamina propria (0–4), inflammatory cell
infiltration (0–4) and crypt abscesses (0–4). For the IL-
4/Stat6 cohorts, the crypt length scores were excluded
due to the fact that we did not have fecal pellet-free
sections available for histology for all mice, which is
needed for accurate measurements. However, for the
sections available, the crypt length scores followed the
same trend as the other colitis sub-scores for each
treatment group.
Immunofluorescence
Paraffin embedded sections were deparaffinized and
rehydrated. For antigen retrieval, sections were
heated in 0.01 M citric acid buffer pH 6 for 10 min
or 30 min at 99°C for cells and tissues respectively.
Non-specific binding was blocked by 5% FBS and the
sections were incubated with an antibody recognizing
the murine and human Muc2/MUC2 mucin (poly-
clonal rabbit-anti-MUC2C3 [2], kind gift of Professor
G. Hansson, University of Gothenburg, Sweden) and
MUC5AC (monoclonal mouse-anti-MUC5AC, 45M1,
Sigma-Aldrich) diluted (1:1000) in blocking buffer
for 2 h at RT. Slides were then incubated for 1 h at
RT with Alexa Fluor 488-conjugated anti-rabbit and
Alexa Fluor 594 anti-mouse immunoglobulins (1:500,
Thermo Fisher Scientific), respectively. For bacterial
localization, sections were co-incubated with mono-
clonal rabbit-anti-E. coli O152 antiserum (295,774,
Denka Seiken) diluted 1:100 and FITC-conjugated
Maackia amurensis lectin II (MAA II, to visualize
mucins, F-7801–2, EY Laboratories) diluted to
25 µg/ml in Tris buffered saline (TBS, 50 mM Tris-
Cl, 150 mM NaCl, pH 7.6) for 1h at RT. Tissue
sections were rinsed three times in TBS and incu-
bated for 1h at RT with Alexa Fluor 594-conjugated
goat anti-rabbit (1:100) followed by three 5 min
washes in TBS. To visualize DNA, the sections were
mounted with DAPI containing Prolong Gold anti-
fade reagent (P36935, Thermo Fisher Scientific).
Pictures were captured with an Eclipse 90i fluores-
cence microscope (Nikon). Quantification of mucin
in the in vitro model was done by measuring the
integrated fluorescence density (the total intensity of
fluorescence in the defined area) obtained by using
the ImageJ program (Wayne Rasband). The percen-
tage of goblet cells was counted in a blinded fashion
at 40x magnification. For bacterial localization, the
tissue section was scored based on O152 density in
the inner mucus layer/in close association with
epithelial cells (Score 1 = >10%, 2 = 10–50% and
3 = >50%) and the total number of crypts colonized
from the neck or epithelial lining and down (Score
1 = 1–3 crypts, 2 = 3–5 crypts and 3 = >5 crypts).
Bacterial density was scored in a blinded fashion at
40x magnification.
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Fluorescence in situ hybridization
The slides were deparaffinized and dehydrated using
increasing concentrations of ethanol. Hybridization
solution (40% (v/v) formamide, 0.1% sodium deodecyl
sulfate, 0.9 M NaCl, 20 mM Tris-HCl pH 7.4) contain-
ing 10 ng/µl of Cy3.5 5´ labeled eubacteria-specific
probe (5´GCTGCCTCCCGTAGGAGT-3´) was added
to tissue sections and incubated at 37°C in a humidified
chamber containing 40% formamide over-night.
Subsequently, the slides were washed with 0.9 M
NaCl, 20 mM Tris-HCl pH 7.4 at 50°C for 20 minutes,
followed by a brief submersion in room temperature
PBS. For co-staining, sections were incubated with
monoclonal rabbit-anti-E. coli O152 antiserum
(295774, Denka Seiken) diluted 1:100 at 4°C over-
night followed by over-night incubation with Alexa
Fluor 594-conjugated goat anti-rabbit diluted 1:100
rinses and reagents were used as mentioned above for
immunofluorescence. Cell mask (C10046, Thermo
Fisher Scientific) diluted (1:14000) in PBS was applied
and sections were incubated for 30 minutes at room
temperature followed by a brief wash in PBS and one in
distilled H2O. DAPI (P36935, Thermo Fisher Scientific)
was used to visualize DNA as described above. Pictures
were captured with an Eclipse 90i fluorescence micro-
scope (Nikon).
Fluorescent detection of GalNAz
Paraffin embedded samples were deparaffinized,
hydrated, and washed in PBS. Membrane sections were
incubated with 20 µl of the reaction mix from the tetra-
mehylrhodamine (TAMRA) glycoprotein detection kit
(C10410, Thermo Fisher Scientific) and incubated at
room temperature for 2 h, followed by wash in PBS. The
sections were mounted with DAPI containing Prolong
Gold anti-fade (P36935, Thermo Fisher Scientific) reagent
to visualize DNA (nuclei). The intensity and localization
of freshly produced mucins were evaluated in a blinded
fashion at 40x magnification on an Eclipse 90i fluores-
cence microscope (Nikon). Due to that co-stain with anti-
body against Muc2 affected the TAMRA intensity, goblet
cells were identified based on cellular morphology.
Evaluation of igg levels in serum by enzyme linked
immunosorbent assay (ELISA)
Serum was obtained from mouse blood samples by cen-
trifugation at 3000 x g for 10min at 4°C. C. rodentiumwas
grown as mentioned above, harvested in sterile PBS,
washed once and sonicated 5 × 15 seconds with a 3 min
interval between sonications. The suspension was then
centrifuged at 4000 x g for 4 min at 4°C, the supernatant
collected, diluted to an OD280 of 0.4 and incubated in
Polysorb ELISA plates (735–0131, Thermo Fisher
Scientific) at 4°C over-night. The plates were washed 3
x in PBS with 0.05% Tween-20 (PBS-t) and unbound sites
were blocked for 1 h in blocking solution (PBS containing
1% BSA). Samples were then plated in triplicates incu-
bated with 100 µl/well murine sera (diluted 1:100, 1:1000,
1:10000 and 1:100000 in blocking solution containing
0.05% Tween-20) for 1h at RT. Plates were then washed
three times in PBS-t and incubated with 100 µl/well HRP
conjugated goat-anti-mouse IgG (115–035-209, Jackson
ImmunoResearch) diluted 1:2000 in blocking solution.
Plates were washed three times in PBS-t and bound sec-
ondary antibody was visualized using
Tetramethylbenzidine substrate reagent (T0440, Sigma-
Aldrich). The reaction was allowed to proceed for 5 min
and then stopped by adding 100 µl of 0.5 M H2SO4.
Absorption at 450 nm was measured (Wallace Victor2,
1420 Multi-label counter, Perkin-Elmer) and background
control (signal in wells without bacterial lysate) was sub-
tracted from the test absorbance.
Flow cytometry analyses
Cells from Mesenteric lymph nodes (MLNs) were
extracted by mashing through a 50 µm filter. Colon
samples of 1.5 cm were harvested as mentioned above
for cell extraction from the lamina propria. For colonic
analyzes, two mice per sample were pooled resulting in
one non-infected control sample and two infected sam-
ples. Colonic tissue was processed as described earlier
[40], but with the use of collagenase VIII (C2139,
Sigma-Aldrich) for digestion. Briefly, colon tissue was
cut into ~5 mm pieces and washed in EDTA
(15575020, Thermo Fisher Scientific) buffer to remove
epithelial cells. Tissue was then digested with collage-
nase and the remaining pieces were mixed with gentle
Table 1. Concentration of cytokines used to treat the in vitro
model. The concentrations of the human cytokines were chosen
based on previous work either related to immune response/
mucin production and/or lack of detrimental effect on cell lines
[33–38].
Cytokine Concentration
Interferon gamma (IFN-γ) 10 ng/ml
Tumor necrosis factor alpha (TNF-α) 10 ng/ml
Interleukin 4 (IL-4) 1.5 ng/ml
Interleukin 6 (IL-6) 15 ng/ml
Interleukin 12 (IL-12) 20 ng/ml
Interleukin 13 (IL-13) 1.5 ng/ml
Interferon gamma (IFN-γ) + Tumor necrosis
factor alpha (TNF-α)
10 ng/ml+10 ng/ml
Interferon gamma (IFN-γ) + Tumor necrosis
factors alpha (TNF-α) + Interleukin 4 (IL-4)
10 ng/ml+10 ng/ml
+1.5 ng/ml
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MACS dissociator. Collected cells from colons and
mesenteric lymph nodes were stimulated with 50 ng/
ml of phorbol myristate acetate (P8139, Sigma-Aldrich)
and 500 ng/ml of ionomycin (I3909, Sigma-Aldrich) at
37°C for 5 hrs in the presence of Golgiplug (555029, BD
Biosciences). Cells were stained with LIVE/DEAD
Fixable Aqua (L34957, Thermo Fisher Scientific), fol-
lowed by surface staining with CD45-APC/Fire750
(clone 30.F11), TCRbeta-BUV737 (H57-597), CD4-AF
700 (GK1.5) and CD8α-BUV395 (53–6.7) purchased
from BD Biosciences and Biolegend. Intracellular stain-
ing of IL-4-Phycoerythrin (11B11, BD Biosciences) was
performed with the FOXP3 staining kit (00–5523-00,
ebioscience). Stained cells were run on Fortessa X20
(BD Biosciences) and analyzed in FlowJo.
Mass spectrometry for GalNAc determination
Cell lysis and protein extraction: Murine colon tissues were
homogenized and the cells lysed in 100 mM Tris-HCl pH
7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
10 mM dithiothreitol and protease inhibitor cocktail
(Sigma Aldrich). Samples were incubated in ice for
15 min, followed by homogenizing twice for one min
with 5 min pause between treatments. Protein extraction
was carried out overnight at 4°C by end-over-end rota-
tion, followed by centrifugation for 30 min, 12,000 RPM
at 4°C. Supernatants containing the soluble extracts were
collected and the protein concentrations were measured
using NanoDrop 2000 (Thermo Fisher Scientific).
Release of O-glycans from extracted proteins:
Approximately 100 µg of extracted protein samples
were dot blotted on a PVDF membrane (Millipore).
Proteins were stained using Alcian blue stain solution,
excised and transferred to an Eppendorf tube.
N-glycans were released from the intact proteins using
10 U N-glycosidase F (PNGase F, Elizabethkingia mir-
icola, Promega) in 20 µl water/tube by overnight incu-
bation at 37°C. The released N-glycans were not used
further in this study. Subsequently, the samples were
subjected to reductive β-elimination with 0.5 M sodium
borohydride in 50 mM sodium hydroxide for 16 h at
50°C to release the O-glycans. The reduction reaction
was quenched by the addition of glacial acetic acid to
the mixtures and desalted using strong cation exchange
resin packed on top of C18 column. The solid-phase
extraction removed cations and any protein or peptide
component remaining. Excess borate was extracted as
methyl esters by repeated evaporation.
Characterization of O-glycans: Released O-glycans
were analyzed by liquid-chromatography-tandem mass
spectrometry (LC-MS/MS) using a 10 cm X 250 µm i.d.
column (in-house), containing 5 µm porous graphitized
carbon (PGC) particles (Thermo Fisher Scientific) con-
nected to an LTQ mass spectrometer (Thermo Fisher
Scientific). O-glycans were eluted using a linear gradi-
ent from 0 to 40% acetronitrile in 10 mM ammonium
bicarbonate over 40 min at a flow rate of 250 nl/min.
Electrospray ionization-mass spectrometry (ESI-MS)
was performed in negative ion polarity with an electro-
spray voltage of 3.5 kV, capillary voltage of −33.0 V,
and capillary temperature of 300°C. The following scan
events were used: MS full scan (m/z 380–2000)
and data-dependent tandem MS (MS/MS) scans after
collision-induced dissociation (CID) on precursor ions
at a normalized collisional energy of 35% with
a minimum signal of 300 counts, isolated width of
2.0 m/z, and activation time of 30 ms. The data were
viewed and manually analyzed using Xcalibur software
(version 2.2, Thermo Fisher Scientific).
Statistics
All tests were performed using Prism (GraphPad
Software, version 3 · 0) or SPSS statistics 18 (IBM).
Values are expressed as mean ± S.E.M or geometric
mean ± interquartile ranges. Comparison of data between
control and infected at a specific time-point was made
using the unpaired t-test or Mann-Whitney U-test. One-
way analysis of variance (ANOVA) with the Holm-
Šídák’s or Dunnet’s multiple comparison or Kruskal-
Wallis tests were used to compare data from more than
2 experimental groups. The analysis of fecal CFU counts
was performed with a linear mixed effects model compar-
ing the slopes of the three treatment groups.
Results
The increased mucus thickness during
C. rodentium clearance is accompanied by
increased mucin production and speed of
transport en route exocytosis in vivo
During C. rodentium infection, the mucus layer initially
becomes thin, as measured at 4 and 10 dpi, followed by an
increase in thickness during clearance, as measured at 14
and 19 dpi [41]. The azide-modified galactosamine
(GalNAz) incorporates into the core region of mucin
O-glycans and can be used to analyze mucin production
and transport [22,42,43]. Newly synthesized mucins can
be visualized in the supranuclear compartment of the cell
one hour after injection [22] and reach the colonic lumen
in 6–8 h [44]. We analyzed quantity and cellular location
of labeled mucins during clearance of infection at 3 h post
GalNAz injection; because by that time the mucins are
inside the cells and potential processing artefacts arising
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in the less stable mucus layer do not affect the analysis.
The level of GalNAz incorporation in the epithelial sur-
face cells doubled during clearance (p < 0.01, Figure 1
(a-e)). The non-goblet cells produce membrane bound
mucins such as Muc4, Muc13 and Muc17, and during
C. rodentium infection Muc1 is induced [13], which likely
contributes to the increased GalNAz incorporation. We
quantified the location of the GalNAz labeled mucins in
the goblet cells separately to investigate if increased Muc2
production could be a contributing factor to the increased
mucus thickness. In non-infected mice, incorporated
GalNAz mainly localized to the supranuclear area in the
Figure 1. Mucin production/transport in the mouse colon during clearance of C. rodentium infection. (a-d) Incorporated GalNAz to
mouse distal colon 3 h after intraperitoneal injection, TAMRA (red) and DAPI (blue). (a) non-infected and (b) C. rodentium infected
mice harvested 14 days after infection using a 20x objective, (c) close-up of goblet cells from the same non-infected and (d) infected
mice using 40x objective. Arrows point to the upper part of the goblet cell theca, which in the non-infected animals is devoid of
GalNAz labelled mucin, whereas in the infected mice incorporated label is abundant. (e) Quantification of the incorporated TAMRA
fluorescence intensity/area in the epithelial surface and neck of the distal colon of WT mice, **p < 0.01,: Mann-Whitney U-test,
n = 6–8 day 14 and 3–4 day 19. (f) Blinded visual semi-quantification of the intensity of incorporated GalNAz in goblet cells, each
location received a score of 0–4 based on intensity, *p < 0.05,: Mann-Whitney U-test, n = 6–8 day 14 and 3–4 day 19. (g)
Quantification of the non-reducing end GalNAc among non-infected control mice and mice infected with C. rodentium for 14 days.
Released O-glycans from distal intestine were analyzed on PGC-LC-MS/MS. Molecular mass, retention time on PGC column and
tandem mass spectra along with in-house tandem mass spectral glycan library were used for structural identification (n = 3).
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goblet cells, although some label was also detected apically
(Figure 1(a, c and f)). The latter represents membrane
bound mucins, which incorporate into the apical cell
membrane faster than the large multimeric mucins
release into the mucus layer [22]. In contrast to the non-
labeled theca of goblet cells in non-infected mice, GalNAz
was mainly found in the mucus theca 14 and 19 dpi
(Figure 1(b, d and f)). Thus, incorporation and transport
of newly synthesized GalNAz labeled mucins through the
goblet cells to the secretory vesicles at the apical surface
was faster in mice at 14 dpi compared to non-infected
mice (p < 0.05, Figure 1(f)), and a similar trend remained
at 19 dpi (p < 0.2). Although the vast majority of GalNAc
are present in the linkage between the protein and the
glycan, they can also be present in the terminal region. To
ensure the increased amount of incorporated label was
not due to changed glycosylation, we analyzed released
O-glycans by liquid-chromatography-tandem mass spec-
trometry (LC-MS/MS). In total, 4 structures containing
non-reducing end GalNAc were detected; 3 of those con-
tained terminal blood group A antigen (GalNAcα1,3
(Fucα1,2)Galβ) and the other one a LacDiNAc epitope
(GalNAcα1,4GlcNAcβ). The relative abundance of these
glycans was less than 4% in total and did not differ
between infected and non-infected mice (Figure 1(g)).
The cytokine environment has a direct impact on
mucus thickness during in vivo infection
To investigate effects of the pathogen versus the cytokine
environment on mucus thickness, we identified that IFN-
γ−/- mice had a similar pathogen burden at 10 dpi (Figure
2(a)), but increased Il-13, Il-5, Il-4, and Il-6 in IFN-γ−/-
mice compared toWTmice [1]. IFN-γ−/- mice had higher
colitis scores (p < 0.001, Figure 2(b) and Supplementary
Figure 1). In non-infected animals, the thickness of the
inner adherent mucus layer was similar in WT and IFN-
γ−/- mice. Ten dpi, the thickness decreased by 20% in WT
mice, whereas it increased by 400% in the IFN-γ−/- mice
(p < 0.01, Figure 2(c)). The infected WT mice had
a decreased amount of stored mucin in the mucosa,
whereas the stored mucin content in the IFN-γ−/- mice
was similar to pre-infection levels (Figure 2(d)). Thus, the
cytokine environment had a stronger influence on the
mucus thickness than the pathogen alone. Similarly to
the mucus changes during different time points of infec-
tion in WT animals [10], Muc1, Muc2, Muc4 or Muc6
mRNA levels did not explain the differences in mucus
thickness between IFN-γ−/- and WT mice
(Supplementary Figure 2). Mucins consist of 90% carbo-
hydrates and mucin production requires a multitude of
glycosyltransferases and is subject to posttranscriptional
regulation. It is thus not surprising that there is no clear
association between levels of mRNA coding for the pro-
tein part of the mucin and mucus thickness or mucin
glycoprotein production. Analogous to the absence of
correlation between mucin mRNA and mucus thickness
found here, a 50% decrease in mucin mRNA levels has
been reported concomitantly with a 3-fold mucin protein
increase in the murine small intestine [45,46].
IFN-γ and TNF-α decreased the integrity and mucin
content of the in vitro mucosal surfaces, whereas
IL-4 and IL-13 enhanced these aspects
To identify cytokines important for mucin production, we
treated in vitromucosal surfaces with polarized goblet cells,
functional tight junctions, three-dimensional architecture
and mucus secretion [31] with cytokines (Table 1) chosen
based on increased expression accompanying increased
mucus thickness (i.e. during clearance or differential
expression in WT versus IFN-γ−/- mice at 10 dpi). The
cytokines were identified from a dataset of 85 genes
involved in Th1/Th2 immune responses from a previous
study using samples from the same mice [1]. The mucosal
surfaces were treated with cytokines for 96 h to mimic the
extended period of elevated cytokine stimulus occurring
during C. rodentium infection in vivo [1]. In a first screen
for the effects of the cytokines associated with increased
mucus thickness on mucin production and goblet cell
density, IL-6 and IL-12 did not induce changes; therefore
we focused on IFN-γ, TNF-α, IL-4 and IL-13. In response
to IFN-γ and TNF-α, the plumpness of the surface goblet
cells and the overall morphology was reduced (p < 0.001),
whereas IL-4 and IL-13 enhanced these features (p < 0.05,
Figure 3(a-f)). Of these four cytokines, IFN-γ, TNF-α and
IL-4 were present in WT animals during clearance,
whereas IL-13 was only detected in IFN-γ−/- mice [1].
To mimic infection in vitro is complex as bacteria
divide fast and absence of mechanisms for eliminating
bacteria result in high bacterial counts, which can be
lethal to epithelial cells. The infecting doses were
titrated to avoid detrimental effects on the epithelial
cells, and yet, we could only accomplish this with
a 24 h infection since longer experiments severely
decreased the trans-epithelial resistance and killed the
epithelial cells, regardless of the infecting dose. To
achieve a viable co-culture, the infecting dose was 20-
fold lower for E. coli than for C. rodentium, due to the
slower growth of the latter. Bacteria were mainly pre-
sent on the apical surface of the in vitro mucosa,
although some were found between cells and basolat-
erally (Figure 3(l-n)). In the presence of C. rodentium,
the cytokines had similar effects on the morphology
and level of stored AB/PAS positive material in the
tissue as in the absence of infection, although the
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responses to cytokines were slightly less pronounced
compared to the non-infected membranes. EPEC and
ETEC infection further blunted the response to the
cytokines, although similar trends could be seen
(Figure 3).
IL-4 protects the goblet cells and mucus
production against the detrimental combined
effect of IFN-γ, TNF-α and infection in vitro
During in vivo clearance ofC. rodentium, the epithelial cells
are exposed to increasing levels of IFN-γ, TNF-α and IL-4
[1]. Treating the in vitro mucosal surfaces with IFN-γ and
TNF-α simultaneously had severe effects on the morphol-
ogy decreasing themean score from 6 to 2 (compare Figure
4 with 3). The combined effects of IFN-γ and TNF-α were
so severe that we lowered the concentration of each cyto-
kine from 10 to 3 ng/ml, since the higher concentration
caused cell death and tissue losses during processing.
Although the mucus related parameter that was most
affected differed between the pathogens, at least one
mucus related parameter that was clearly improved by IL-
4 treatment in each infection: inC. rodentium infected IFN-
γ and TNF-α treated membranes the AB/PAS score
Figure 2. C. rodentium infection parameters, intracellular mucin storage and mucus thickness in WT and IFN-γ−/- mice. (a) Colony
forming units (CFU) of C. rodentium were analyzed in fecal pellets collected from individual mice. Compared to the non-infected
mice, the number of C. rodentium increased in both WT and IFN-γ−/- mice after infection. The CFU counts only differed between the
groups at day three, and were indistinguishable at day five and 10 pi (n = day 0: IFN-γ−/- 10 and WT 4, days three and five: 3–4, day
10: IFN-γ−/- 16 and WT 4). (b) Colitis scores for WT and IFN-γ−/- mice during infection. The score is calculated from the sum of crypt
architecture, increased crypt length, emptied goblet cells, leukocyte infiltration, presence of lamina propria neutrophils, crypt
abscesses, and epithelial damage and ulceration (Score 0–4/parameter) (n = day 0: IFN-γ−/- 9 and WT 26, day 10: IFN-γ−/- 10 and WT
19). (c) The thickness of the inner mucus layer in distal colonic explants of WT and IFN-γ−/- mice in the non-infected animals at day 0
and 10 pi (n = IFN-γ−/- 4 and WT 7) assessed by measuring the distance between the top of the mucus layer (visualized by addition
of activated charcoal particles) and the epithelial surface using a micropipette connected to a micromanipulator. D) The percentage
of the mucosa positive for AB/PAS staining in the colon of the WT and IFN-γ−/- mice (n = IFN-γ−/- 9–10, WT day 0: 21 and day 10: 18).
Statistics: one way ANOVA, Holm-Šídák’s post hoc test, ##p < 0.001, ###p < 0.0001 vs day 0 of the WT mice, *p < 0.05, **p < 0.01,
***p < 0.0001 vs day 0 of the IFN-γ−/- mice and &p < 0.05, &&&p < 0.0001 vs day 10 of the WT mice.
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increased by 50% (p < 0.05, Figure 4(a)), in EPEC infected
ones the AB/PAS score doubled (p < 0.05, Figure 4(a)) and
the intensity of the MUC2/MUC5AC stain increased 10-
fold (p < 0.05, Figure 4(c)). In ETEC infected membranes
the amount of goblet cells increased 24-fold (p < 0.05,
Figure 4(b)). The differences between the infections are
likely related to that the severity of the infection differed
between pathogens or to inherent differences in host-
pathogen interactions between the pathogens. The scenario
most relevant to the in vivo C. rodentium infection is most
likely that of EPEC, as this is an attaching and effacing
pathogen interacting with cells from its natural host.
In vitro mucin production and transport from Golgi
to secretory vesicles at the apical surface is
enhanced by IL-4 and infection
We compared incorporation and cellular localization of
GalNAz labeled mucins at 2 h post addition of label (as
a proxy for transport speed from Golgi to release at the
apical surface), as the labeled mucins at that time mainly
were inside the cells. In the absence of infection, addition
of IFN-γ and TNF-α trended towards decreasing the
amount of incorporated label, IL-13 had no apparent
effect, while IL-4 increased the mucin production and
transport speed en route exocytosis (p < 0.001, Figure
5). Although the effect of infection differed slightly
between pathogens and which cytokine it was combined
with, the overall effect of infection was increased mucin
production and transport speed (p < 0.001). Infection
with ETEC not only reversed the tendency to inhibition
caused by IFN-γ, but enhanced the mucin transport
(p < 0.05), and a similar trend was also found with
C. rodentium. IL-4 and IL-13 increased the production
further in the presence of infection (p < 0.05, Figure 5).
IL-4+ T cells contribute to increased IL-4 expression
and the mucus increase most likely occurs via the
IL-4-receptor α/Stat6/Spdef pathway in vivo
The results above imply that IL-4 contributes to increased
mucus thickness during clearance in WT mice, whereas
both IL-4 and lL-13 may contribute to the increased
thickness in IFN-γ−/- mice at day 10 pi. To investigate
the source of IL-4, we used flow cytometry for intracel-
lular IL-4 staining on lymphocytes from the colon and
Figure 3. Morphology score of in vitro mucosal surfaces with and without C. rodentium, EPEC or ETEC infection. (a) Score reflecting
the morphology (based on number of crypt like structures 0–4, integrity of the epithelial layer 0–4, and presence and mucus
engorgement of surface goblet cells 0–4). Statistics: one way ANOVA, Dunnett’s post hoc test, *p < 0.05, **p < 0.001 and
***p < 0.0001 compared to controls in each group, and one way ANOVA, Holm-Šídák’s post hoc test, &p < 0.05, &&p < 0.001
compared to the non-infected in vitro mucosal surfaces treated with the same cytokine (n for non-infected: control 23, IFN-γ 12, TNF-
α 12, IL-4 13, IL-13 11, for C. rodentium infected: control 9, IFN-γ 12, TNF- α 11, IL-4 13, IL-13 8, for EPEC infected: control 9, IFN-γ 5,
TNF- α 6, IL-4 6, IL-13 5, for ETEC infected: control 5, IFN-γ 5, TNF- α 5, IL-4 5, IL-13 5), results are the mean of three experiments. B-K)
AB/PAS staining of in vitro mucosal surfaces: B) Non-infected and non-treated, (c) treated with IFN-γ, (d) TNF-α, E) IL-4, (f) IL-13, (g)
C. rodentium infected non-treated, (h) treated with IFN-γ, (i) TNF-α, (j) IL-4 and (k) IL-13. The in vitro mucosal surfaces were stained
with Eub338 (green) and cell mask (red) to visualize bacterial localization in relation to the epithelial cells after 24 h of infection with
(l) C. rodentium, (m) EPEC or (n) ETEC, nucleus stained with DAPI (blue).
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MLNs. The frequency of IL-4+ cells in MLNs ranged from
0.5% to 1.4% for CD4+ T cells and 0.7% to 2.5% for CD8+
T cells, with no difference between the non-infected con-
trol animals and the C. rodentium infected animals. The
frequencies of IL-4+ T cells in the colon were higher
compared to MLNs (4.0% to 5.7% for CD4 and 4.3% to
6.5% for CD8, Supplementary Figure 3(a)), but again no
difference was observed between the controls and infected
animals. However, we observed a 4-fold increase in the
T cell frequencies among live CD45+ cells in infected
animals compared to the controls, and the larger absolute
numbers of IL-4+ T cells in the infected animals could
Figure 4. Combined IFN-γ and TNF-α in vitro treatment with and without addition of IL-4. The in vitro mucosal surfaces were
cytokine treated for 4 days and infected for 24 h. (a) AB/PAS score: the score reflects the morphology (based on number of crypt like
structures 0–4, integrity of the epithelial layer 0–4, and presence and mucus engorgement of surface goblet cells 0–4). (b, c) MUC2
and MUC5AC immunofluorescence; B) The percentage of the cells in the in vitro mucosal surfaces that were goblet cells was
calculated in a blinded fashion. The white versus black parts of the bar corresponds to the proportion of the goblet cells that were
positive for MUC5AC versus MUC2. Most goblet cells were positive for both mucins, although some only for one mucin. (c)
Integrated fluorescence density obtained using the ImageJ program to quantify the mucins in the in vitro mucosal surface. Statistics:
Wilcoxon signed rank test, *p < 0.05 (n = 3–5).
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contribute to the increased IL-4 expression in the colon
(Supplementary Figure 3(b)).
IL-13 induce airway mucus production via the IL-
4-receptor α, Stat6 and the SAM pointed domain-
containing ETS transcription factor, (Spdef) pathway
[47,48]. An mRNA array demonstrated that IL-4, IL-
4-receptor α, and Stat6 transcription levels were increased
both in the IFN-γ−/- mice 10 dpi (but not in the WTmice
at the same time), and in WT mice at 14 and 19 dpi
(Figure 6(a)). Using the Search Tool for the Retrieval of
Interacting Genes/Proteins database, we identified further
Stat6 associated proteins among the ones that were upre-
gulated in the array (Figure 6(a, b)), and finally qPCR on
individual mice confirmed that Spdef and Stat6 were
upregulated during clearance of infection (p < 0.05,
p < 0.01 Figure 6(c)). The toll-like receptor initiated path-
way via Myd88 and NfκB has also been described to
induce airway mucus secretion, and these genes trended
towards being upregulated during clearance (p = 0.13 and
0.12, Figure 6(c)). Thus, the in vivo increase in goblet cells,
mucus production and transport rate potentially occur via
the IL-4/IL-4-receptor α/Stat6/Spdef pathway, although
other pathways may also contribute.
In vivo manipulation of the IL-4/Stat6 pathway
affects colitis, pathogen localization and mucus
thickness and quality
We initiated treatment with Stat6 inhibitor or IL-4 at
10 dpi to mimic a situation likely for a therapeutic
regimen. All mice were colonized and soft stools were
observed from day four pi onwards, with no clear
difference between the treatment groups. C. rodentium
infected mice treated with IL-4 for 3 consecutive days
had lower colitis scores than vehicle or Stat6 inhibitor
treated mice at 13 dpi (p < 0.05) and by 22 dpi the
colitis scores of both vehicle (p < 0.005) and IL-4
(p < 0.05) treated mice had decreased, whereas the
scores of Stat6 inhibitor treated mice remained high
(Figures 7(a) and 8(a–d)). Furthermore, the level of
inflammatory cell infiltration was lower in IL-4 treated
mice compared with vehicle treated ones at 13 dpi
(p < 0.05, Figure 7(b)). C. rodentium specific serum
immunoglobulin G (IgG) increased to similar levels in
all three infected treatment groups (p < 0.05, Figure 7
(c)). The fecal CFUs decreased in all animals, regardless
of treatment group: estimating the decrease of fecal
CFU with a linear mixed effects model from day 10 to
18, the slopes were −0.58, −0.60 and −0.50 log units/day
for vehicle, IL-4 and Stat6 inhibitor treated groups,
respectively (Figure 7(d)). Furthermore, the amount of
E. coli LPS O152 positive bacteria (also present in
C. rodentium) in close association with the epithelium
and in the inner mucus layer was abundant in infected
vehicle and Stat6 inhibitor treated mice (p < 0.01),
whereas they were almost absent in these locations in
IL-4 treated mice and not statistically different from the
non-infected mice at 13 dpi (Figure 8(e-m)). Although
very few O152 positive bacteria were present in asso-
ciation with the epithelial cells or the inner mucus layer
in the non-infected mice (Figure 8(i–m)), we detected
O152 positive bacteria in the fecal pellet
(Supplementary Figure 4(e, i and m). In non-infected
mice, O152 negative bacteria formed large aggregates
Figure 5. Mucin production and transport en route exocytosis in cytokine treated in vitro mucosal surfaces with and without
infection. In vitro mucosal surfaces were harvested two h after addition of GalNAz to the basolateral media and the intensity and
cellular location of incorporated label were detected by immunofluorescence. Scores for intensity and location of newly synthesized
mucins were calculated as: close to nucleus (0–4), in the lower half of the cytoplasm (0–4), in the upper half of the cytoplasm (0–4)
and at the cell surface (0–4) in a blinded fashion. Statistics: one way ANOVA, Dunnett’s post hoc test, *p < 0.05 and **p < 0.01
compared to control in each group, and one way ANOVA, Holm-Šídák’s post hoc test, &&p < 0.001 and &&&p < 0.0001 compared to
the non-infected in vitro mucosal surfaces treated with the same cytokine (n = 3–4).
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and dominated the fecal flora, but at 13 dpi these large
aggregates were absent in all infected mice, regardless
of treatment, although O152 negative bacteria remained
present. O152 positive bacteria were present at a high
density in feces from vehicle and Stat6 inhibitor treated
infected mice whereas a low density was observed in
feces from IL-4 treated mice (Supplementary Figure 4),
analogous with the tendency to fewer C. rodentium
detected by fecal CFU counts in these mice.
In contrast to vehicle or Stat6 inhibitor treated mice,
the mucus layer in IL-4 treated mice appeared thick
and organized in a similar fashion as in the non-
infected mice (Figure 8(e-h)). Ex vivo live imaging of
mucus on colonic mucosa supported that infected IL-4
treated mice had a mucus layer thicker than vehicle
treated infected mice at 13 dpi (p = 0.056, Figure 8(n,
p)). Although the mucus allowed bacteria-sized fluor-
escent beads to penetrate, the function of the mucus in
infected IL-4 treated mice was better than in vehicle
treated mice since more beads reached the epithelium
in vehicle treated infected mice (p < 0.05, Figure 8
(o, p)).
Discussion
In the present study, we revealed that changes in the
cytokine environment induce increased production and
transport of mucins from the Golgi to the secretory
vesicles at the apical surface during clearance of infec-
tion. During C. rodentium infection, IFN-γ−/- mice had
similar pathogen burden, but different cytokine envir-
onment, 4-fold thicker mucus layer and more stored
mucin in the tissue than WT mice, demonstrating that
the cytokine environment impacts mucus thickness
during intestinal infection in vivo. Neither the
enhanced mucus thickness found during clearance in
the WT mice [41], nor the increased mucus thickness
observed in the IFN-γ−/- mice during infection could be
Figure 6. Expression of genes involved in mucin regulatory pathways during C. rodentium infection. (a) Changes in mRNA levels of
infected WT (10, 14 and 19 dpi) and IFN-γ−/- (10 dpi) mice, expressed as mean fold change compared to non-infected controls and
based on a qPCR cytokine array containing 84 mouse inflammatory cytokines, chemokines and receptor genes. The data sets for time
point 0 and 10 dpi represents four mice (pooled two and two) and the time points 14 and 19 dpi are representative of three mice.
The differences between the data sets (biological and technical replicates) at each time point were less than 15%. Expression data
was normalized against the Gusb housekeeping gene, which was calculated to be the most stable of the five existing housekeeping
genes in the array. B) Interaction network of the proteins encoded in the mRNA array that were connected to Stat6, generated by
the STRING v10database (https://string-db.org). The lines connecting each node were weighted for confidence of interaction based
on experimental datasets and published information. Stronger associations are represented by thicker lines. (c) mRNA levels
determined by qPCR in an additional three WT mice 0 and 19 dpi. Gene expression was normalized against Hhprt and
Eif2 housekeeping genes. Fold changes were calculated using ΔΔCT with the mean CT from non-infected control mice. Statistics:
unpaired t-test *p < 0.05 and **p < 0.01 (n = 3).
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explained by changes in mucin mRNA levels. Instead,
experiments on in vitro mucosal surfaces showed that
the local cytokine environment, namely IL-4, and infec-
tion have major effects on mucin production and trans-
port speed. Increased expression of Il-4, Il-4-receptor α,
Stat6 and Spdef, indicate that this pathway may be
responsible for the increase in mucus production and
transport speed, and manipulating this pathway
affected mucus thickness and quality as well as the
amount of bacteria in close contact with the host
epithelial cells and colitis levels.
IL-4 is produced by T cells, mast cells and basophils
and has many biological roles in innate and adaptive
immunity. Of particular relevance to the current study,
IL-4 contributes to increased antibody responses after
infection [49]. In the airways, IL-13 has been shown to
induce mucus production via the IL-4-receptor α, Stat6
and Spdef pathway [47,48]. This pathway has been
implicated in healing, but with contrasting results: IL-
4 has been demonstrated to impair wound healing in
the skin [50], whereas Stat6−/- mice display delayed
wound healing in mice treated with 2,4,6-trinitroben-
zenesulfonic acid [51]
We have previously shown that mucin production
and vesicle transport rate decrease during acute and
chronic infection with Helicobacter pylori in the murine
stomach [52]. Similar to C. rodentium, H. pylori is
associated with a Th1/17 cytokine response, but in
contrast, H. pylori causes a chronic infection associated
with reduced expression of IL-4 [53]. When the mucus
thickness increases, concomitantly with the increase in
mucin production and transport during clearance of
Figure 7. Effect of IL-4 and Stat6 inhibitor treatment on colitis, serum IgG and fecal CFU in C. rodentium infected WT mice. Mice
received IL-4 (0.2 µg/mouse), Stat6 inhibitor (AS1517499, 10 mg/kg body weight [26]) or vehicle (sterile PBS containing 20% DMSO
and 1% bovine serum albumin) by intraperitoneal injection for three consecutive days (for cohort 1: from day 11 to day 13, cohort
2: day 10 to day 12 pi). (a) Colitis scores for all treatment groups at 13 and 22 (clearance of infection ≤1000 CFUs/g feces) dpi. The
score is the sum of crypt architecture, goblet cell depletion, leukocyte infiltration, presence of lamina propria neutrophils, crypt
abscesses, and epithelial damage and ulceration. Results are shown from cohort 2 (n = 5–6/group and time point), and similar
results were obtained from cohort 1 (n = 4–5/harvested day 14). (b) Inflammatory cell infiltration at 13 dpi (n = 5–6, cohort 2). (c)
Mouse serum IgG response to C. rodentium determined by ELISA at 13 dpi (n = infected vehicle, Stat6 inhibitor and IL-4 treated 5–6,
non-infected control 8). Statistics: Kruskall wallis test; *p < 0.05 vs vehicle, &p < 0.05 IL-4, ††p < 0.01 vehicle and ##p < 0.01 Stat6
inhibitor vs non-infected control. (d) Fecal C. rodentium CFU counts from infected groups: non-infected control mice were excluded
as they did not have any C. rodentium colonies. Results shown are pooled from cohort 1 and 2 (n = 12–16/group until day 14 and
4–6/group until day 22). The analysis of fecal CFU counts was performed with a linear mixed effects model comparing the slopes of
the three treatment groups (p = 0.44).
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Figure 8. Effect of IL-4 and Stat6 inhibitor treatment on mucus thickness and quality and bacterial localization in WT mice.
Representative images of H&E stained mouse distal colon samples from (a) non-infected non-treated, (b) infected vehicle, (c) infected Stat6
inhibitor and (d) infected IL-4 treated mice. Images were taken with a Nikon Eclipse 90i microscope, using a 20x objective. (e-h) Muc2
(green) immunofluorescence images showing (e) an organized, dense inner mucus layer (IM, highlighted in dotted lines) in non-infected
non-treated control mice and (h) infected IL-4 treated mice, whereas F) the IM is poorly defined in infected vehicle and (g) Stat6 inhibitor
treated mice at 13 dpi (n = 10, images representative for cohorts 2 and 1). (i-l) Localization of O152 positive bacteria (red) in distal colon
(mucus stained with MAA II-lectin, green) in (i) non-infected control and (j) infected mice treated with vehicle, (k) Stat6 inhibitor or (l) IL-4 at
13 dpi (arrowheads point to bacteria). Images were captured using a 40x objective (n = 10, images representative for cohorts 2 and 1). (m)
Quantification of bacterial localization in close association with the inner mucus layer/surface epithelial cells and crypts at 13 and 14 dpi
(n = 10, results pooled from cohorts 1 and 2). N-P) Ex vivo imaging and analysis of mucus in the distal colon of infected vehicle and IL-4
treated mice using 1 µm beads; inner mucus layer thickness (n), penetrability of 1 µm sized beads (o) and representative images (1 µm sized
beads: red, epithelium: blue) using an LSM700 confocal microscope at 20x objective (p) at 13 dpi (n = 5). Please note that mucus thickness
in Figure 2 cannot be compared to the data presented here due to that the hydrophobic charcoal used for that measurement floats on top
of the mucus, whereas the measurement of the inner mucus layer presented here use beads with ability to penetrate mucus with an altered
structure. Statistics: (m) Kruskall wallis test; *p < 0.05, **p < 0.01, ***p < 0.001 vs non-infected control, and (n and o) Mann-Whitney U-test.
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C. rodentium, the environment is no longer of a typical
Th1/17 cytokine profile, but also contains Th1/17-
opposing cytokines, including IL-4.
In vitro, IL-4 and IL-13 generally had positive effects
on mucin production and transport, whereas IFN-γ
and TNF-α had negative effects, although the negative
effects were partially counteracted by the presence of
pathogens, demonstrating a concerted regulation of
these events. In a previous study using an allergic
model, Th2 cells intravenously transferred into mice
resulted in high levels of IL-4 and increased levels of
AB/PAS stained mucins in the tissue [54]. In contrast,
transfer of twice the number of Th1 as Th2 cells
decreased the amount of AB/PAS stained mucins in
an IFN-γ receptor dependent manner [7]. Although
these results only depict the level of mucin in tissue,
they are in line with the thinner mucus layer and lower
amount of stored mucin in the colon of the infected
WT mice compared to IFN-γ−/- mice found in this
study. However, in C. rodentium infected WT mice,
an increase in the mucus thickness occurs from 14
dpi throughout 19 dpi [41]. This stands in contrast to
IFN-γ as a negative regulator of mucus thickness since
we also observed a successive increase in Ifn-γ mRNA
throughout clearance of the pathogen. This increase in
mucus layer thickness starts after 10 dpi, which is the
time point when the bacteria reach the highest density
in the lumen, mucus thickness reduced to its lowest
level, and an organized striated inner mucus layer was
rarely found [41]. The absence of a protective barrier as
well as high bacterial density likely lead to that an
abundance of bacterial products reaches the epithelial
cells. Indeed, in vitro infection in combination with
IFN-γ enhanced mucin production and transport
through the cell en route exocytosis, in contrast to the
decrease caused by IFN-γ alone. Therefore, the bacter-
ial stimulation together with the concomitant increase
of IL-4 and IFN-γ are likely the reasons for the
increased mucus thickness during C. rodentium clear-
ence. Tnf-α was up-regulated during the clearance
phase of infection, coinciding with an enhanced
mucus layer (14 and 19 dpi) in WT mice. Treating
the in vitro mucosal surfaces with this cytokine had
similar effects on mucus production as IFN-γ, decreas-
ing the number of goblet cells, mucus thickness and
transport. Furthermore, the combination of IFN-γ and
TNF-α damaged the integrity of the epithelial surface
and reduced the number of goblet cells. This damaging
effect is in line with the result of a study on the C1.16E
cell line cultured as a monolayer that showed treatment
with these cytokines flattens the cells and devoid them
of mucus granules [9]. Although there are sloughed off
goblet cells present throughout infection and clearance
in vivo [13], the presence of IL-4 appears to be a factor
limiting the negative effects of these cytokines, and
indeed IL-4 has previously been shown to protect the
mucosal mitochondrial activity during C. rodentium
infection [1].
Of the cytokines upregulated during times of an
enhanced mucus layer, IL-4 was the most efficient
enhancer of goblet cell numbers, surface goblet cell
engorgement, as well as production and transport rate
of mucin vesicles through the cell. This is in contrast to
worm (Trichinella spiralis) infection, during which IL-
13, but not IL-4, is affecting murine goblet cell prolif-
eration [6], pointing to that the combined effect of the
pathogens and the immune system determines the
mucin/mucus changes during infection. IL-13 may
however contribute to the vastly increased mucus thick-
ness in the IFN-γ−/- mice at 10 dpi, as both IL-4 and IL-
13 increased in these mice. In addition to enhancing
mucin production and transport, IL-4 also had
a protective effect on the integrity of the in vitro muco-
sal surface, goblet cell number, and the amount of
mucin produced during infection. Increased levels of
Il-6 mRNA occurred both in C. rodentium infected
IFN-γ−/- mice at day 10 pi, and in the WT mice
at day 14 and 19 pi, coinciding with the increase in
mucus thickness in both systems. Although IL-6 in
other contexts has been shown to phosphorylate Stat6
[55], addition of IL-6 alone had no effect on any of the
measured mucus related parameters in the in vitro
mucosal surfaces. Previous studies have shown that
IL-6 contributes to polarization of naive CD4+ T cells
to effector Th2 cells which then initiate production of
IL-4 [56]. Thus, IL-6 may enhance the mucin produc-
tion via induction of IL-4 in vivo.
Together, the data suggests that the in vivo
increase in mucus production and transport speed
may occur via the IL-4/IL-4-receptor α/Stat6/Spdef
pathway, and manipulating this pathway affects
mucus penetrability, thickness, and pathogen locali-
zation in vivo. Although members of this pathway
affect functions in B cells, T cells and macrophages,
and the effect on bacterial location thus cannot be
certified to solely depend on the increase in mucus
production and transport, these results support the
in vitro data that this pathway plays an important
role during clearance of infection. Mucolytic agents
have bactericidal and antioxidative effects [57,58],
making it difficult to prove that the increase in
mucus production is the only cause for the decreased
pathogen burden in IL-4 treated mice. However,
C. rodentium infection in mice lacking Muc2 results
in high mortality [11], mice with defective mucus
exocytosis display delayed C. rodentium clearance
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[12] and C. rodentium bind to murine Muc2 [13].
These findings, together with our observation that
IL-4 treatment increase mucus thickness and quality
and decrease colitis and the number of pathogens in
contact with the epithelium, demonstrate that mucus
secretion is important for C. rodentium clearance.
B-cell deficient mice infected with C. rodentium fail
to clear the infection and IgG is important for infec-
tion clearance [14,15]. However, the amount of
C. rodentium specific serum IgG was similar in
infected mice regardless of IL-4, Stat6 inhibitor or
vehicle treatment, suggesting that the effects seen in
this study were not due to changes in IgG levels.
Furthermore, IL-4 has previously been shown to
inhibit macrophage killing of C. rodentium [59], sug-
gesting that the IL-4 treated mice would be at
a disadvantage, if the epithelial cell response was
not of importance. The microbiota has been shown
to be important for clearance of C. rodentium infec-
tion, since germ free mice do not clear the infection,
but addition of commensals aid in removal of the
infection/pathogen when added after the normal
clearance time [60]. Since germ free mice have
a thin disorganized mucus layer [61], these results
are compatible with a clearance model where IL-4
dependent mucus and defensive factors secreted
into the mucus aid in removing the pathogen from
the epithelial surface, and once the pathogen is in the
lumen, the recovering commensal flora aids by out-
competing the pathogen. The beneficial role of IL-4 is
in line with a study demonstrating a correlation
between increased IL-4 levels and short duration of
ETEC infection [62]. Furthermore, IL-4 administra-
tion had beneficial effects in both animal houses used
in this study. Although the facilities used were rela-
tively similar, some factors, such as the microflora,
are likely to differ. This suggests that the effect of IL-
4 is of general nature.
The IL-4 treatment started at height of infection and
three days of treatment led to that the pathogen was
removed from the colonic epithelial surface earlier than in
vehicle or Stat6 inhibitor treated mice and this was accom-
panied by a 30%decrease in colitis. Prophylactic rather than
therapeutic treatments generally lead to more pronounced
effects, however, the latter is more relevant from a clinical
perspective. The removal of the pathogen from the epithe-
lial surface and recovery of a functionalmucus layer ismore
important for healing than the presence of pathogen in the
fecal pellet as pathogens can be present in the lumen for
long periodswithout causing symptoms and can remain for
months after recovery from an infectious disease. Indeed,
both in murine colitis models and ulcerative colitis, bacter-
ial penetration of the normally impenetrable mucus layer
and access to the epithelium are important determinants of
colitis [3]. In addition to colitis, ETEC and EPEC infection
also cause diarrhea. The mouse strain used in the current
study did not develop watery diarrhea but instead, semi-
solid fecal pellets were observed with the infectious dose
used here. A more susceptible mouse model, such as FVB/
N might be more appropriate to study the effect of treat-
ments on diarrhea [63].
In conclusion, our results demonstrated that the cyto-
kine profile and pathogen species act in concert to impact
several parameters that affectmucus thickness. IL-4was the
cytokine that demonstrated most beneficial effects, both
with regards to mucin production parameters, and also in
that it protected epithelial surface integrity in vitro against
the detrimental effects of IFN-γ, TNF-α and the presence of
pathogens. Thus, during clearance of infection, the increase
in IL-4maintains goblet cell function and protects it against
the increasing levels of TNF-α and IFN-γ. Furthermore, the
IL-4/Stat6 pathway is an important determinant of intest-
inal mucus production that can be manipulated and affect
bacterial localization. Manipulating this pathway may thus
be a therapeutic option to enhance healing of the mucosa
and shorten the duration of infections, or to induce healing
during chronic infections.
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